ObsEva Stays Afloat By Selling Lead Women’s Health Asset To XOMA
For $15m Upfront
The Swiss firm has divested yet another one of its key programs in a bid to stave off insolvency and remain a listed company, forcing it to focus solely on a pre-IVF drug candidate.
